Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

Core Insights - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [2] Group 1: Upcoming Conferences - Company management will participate in the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 11:20 a.m. ET [1] - The company will also attend the 2026 Jefferies Biotech on the Beach Summit on March 10, 2026, for investor meetings [1] - A live webcast of the Leerink fireside chat will be available on the company's website, with a replay accessible for 90 days post-conference [1] Group 2: Company Overview - Kyverna's lead therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), targets CD19 and aims to change treatment paradigms for B-cell-driven autoimmune diseases [2] - The company is advancing a neuroimmunology franchise with initial indications in stiff person syndrome and myasthenia gravis [2] - Additional studies are being conducted in multiple sclerosis and rheumatoid arthritis to inform future indications and develop next-generation CAR T platforms [2]